Stefano Del Prato
YOU?
Author Swipe
View article: Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes
Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes Open
View article: Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management Open
View article: Diabetes registries—key enablers of high-quality care
Diabetes registries—key enablers of high-quality care Open
View article: Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4
Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4 Open
This post hoc analysis assessed sustainability of lowered glycated hemoglobin (HbA1c) and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. Participants achieving HbA1c ≤48 mmol/mol (6.5%) or weight …
View article: <b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b>
<b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b> Open
This post hoc analysis assessed sustainability of lowered HbA1c and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. Participants achieving HbA1c ≤48 mmol/mol (6.5%) or weight loss ≥10% at 52 weeks …
View article: <b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b>
<b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b> Open
This post hoc analysis assessed sustainability of lowered HbA1c and weight with tirzepatide in people with type 2 diabetes and increased cardiovascular risk. Participants achieving HbA1c ≤48 mmol/mol (6.5%) or weight loss ≥10% at 52 weeks …
View article: Effect of Efpeglenatide on Heart Failure Outcomes: A Participant-Level Exploratory Analysis of the Randomized AMPLITUDE-O Trial
Effect of Efpeglenatide on Heart Failure Outcomes: A Participant-Level Exploratory Analysis of the Randomized AMPLITUDE-O Trial Open
View article: European Association for the Study of Diabetes (EASD) Standard Operating Procedure for the development of guidelines
European Association for the Study of Diabetes (EASD) Standard Operating Procedure for the development of guidelines Open
The European Association for the Study of Diabetes (EASD) has developed a Standard Operating Procedure (SOP) for the development of clinical practice guidelines, ensuring adherence to rigorous methodological standards based on the principl…
View article: Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001 Open
View article: Obesity and its management in primary care setting
Obesity and its management in primary care setting Open
View article: Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report Open
Background The treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improv…
View article: Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis
Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis Open
BACKGROUND: Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary exercise characteristics of i…
View article: Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review Open
Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person…
View article: Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial Open
Background Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF is defined by abnormal LV morphology and …
View article: Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—‘ <scp>eCGM</scp> ’ compliance status
Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—‘ <span>eCGM</span> ’ compliance status Open
View article: An International Debt Architecture and Debt Sustainability Assessments as if People and Planet Mattered
An International Debt Architecture and Debt Sustainability Assessments as if People and Planet Mattered Open
View article: Beta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance
Beta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance Open
Introduction Previous studies have suggested an association between beta-cell and autonomic function and metabolic-associated fatty liver disease (MAFLD). We explored the association between controlled attenuated parameter (CAP) and insuli…
View article: Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial Open
In high-risk people with type 2 diabetes, the degree of liver fibrosis, as estimated by FIB-4 score, was not related to incident cardiovascular outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of FIB-4 cate…
View article: Che cosa non sappiamo sugli SGLT-2 inibitori
Che cosa non sappiamo sugli SGLT-2 inibitori Open
Sommario Gli inibitori del co-trasportatore sodio-glucosio 2 (SGLT2i) sono farmaci utilizzati per il trattamento del diabete di tipo 2 che hanno dimostrato importanti benefici cardiorenali. Nonostante l’impiego crescente di questa classe d…
View article: Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care Open
View article: Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy
Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy Open
View article: Racial Differences in Diabetic Cardiomyopathy
Racial Differences in Diabetic Cardiomyopathy Open
View article: GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes Open
View article: 2024: The year to take European action on diabetes to the next level
2024: The year to take European action on diabetes to the next level Open
View article: Indirect effects of the COVID-19 pandemic on diagnosing, monitoring, and prescribing in people with diabetes and strategies for diabetes service recovery internationally
Indirect effects of the COVID-19 pandemic on diagnosing, monitoring, and prescribing in people with diabetes and strategies for diabetes service recovery internationally Open
The COVID-19 pandemic has caused major disruptions in clinical services for people with chronic long-term conditions. In this narrative review, we assess the indirect impacts of the COVID-19 pandemic on diabetes services globally and the r…
View article: Beta-cell function, incretin effect and glucose kinetics in response to a mixed meal in patients with type 2 diabetes treated with dapagliflozin plus saxagliptin
Beta-cell function, incretin effect and glucose kinetics in response to a mixed meal in patients with type 2 diabetes treated with dapagliflozin plus saxagliptin Open
Objective - To explore complementary effects of DPP-4 and SGLT2 inhibitors combination as add on to metformin on hormonal and metabolic responses to meal ingestion. Research Design and Methods - Forty-five patients (58±8 y, HbA1c: 58±6 mmo…
View article: Beta-cell function, incretin effect and glucose kinetics in response to a mixed meal in patients with type 2 diabetes treated with dapagliflozin plus saxagliptin
Beta-cell function, incretin effect and glucose kinetics in response to a mixed meal in patients with type 2 diabetes treated with dapagliflozin plus saxagliptin Open
Objective - To explore complementary effects of DPP-4 and SGLT2 inhibitors combination as add on to metformin on hormonal and metabolic responses to meal ingestion. Research Design and Methods - Forty-five patients (58±8 y, HbA1c: 58±6 mmo…
View article: Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus Open
View article: Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy Open
View article: Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study
Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study Open